Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumateperone for Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
NCT06690398Phase 3Recruiting
- Sponsor
- Intra-Cellular Therapies
- Start
- Nov 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of lumateperone in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Intra-Cellular Therapies. Primary endpoint: Aberrant Behavior Checklist - Irritability at 6 weeks. Started Nov 2024; status: recruiting.
02
Drugs
lumateperone
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT06690398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06690398.